13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001835943
Total reported value
$1.6B
$1.6B
34 檔
12.4%
As reported in its official Q4 2025 Form 13F filing, AIGH Capital Management LLC's tracked investment portfolio stood at $1.6B with 34 total positions.
AIGH Capital Management LLC executed strategic sector rebalancing during Q4 2025, establishing 9 new positions while fully exiting 12 holdings and trimming 9 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SNDK | Sandisk CORP | Stock-Tech | 16.09% | +4.02% | — | |
| 2 | ZM | Zoom Communications, Inc. | Stock-Tech | 14.62% | — | — | |
| 3 | CSTL | Castle Biosciences Inc | Stock-Other | 5.88% | -1.16% | -11.67% | |
| 4 | PSNL | Personalis Inc | Stock-Other | 5.59% | -1.07% | -25.49% | |
| 5 | LASR | Nlight Inc | Stock-Other | 5.45% | -2.64% | EXIT | |
| 6 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 4.49% | — | +31.01% | |
| 7 | VNDA | Vanda Pharmaceuticals Inc | Stock-Other | 4.27% | -1.80% | — | |
| 8 | BKTI | Bk Technologies CORP | Stock-Other | 3.82% | -0.33% | EXIT | |
| 9 | DOMO | Domo Inc - Class B | Stock-Other | 3.75% | +0.57% | NEW | |
| 10 | ESPR | Esperion Therapeutics Inc | Stock-Other | 3.58% | -1.64% | EXIT | |
| 11 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 3.41% | -0.78% | — | |
| 12 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 2.95% | +0.02% | +132.06% | |
| 13 | LPTH | Lightpath Technologies Inc-a | Stock-Other | 2.69% | -0.14% | EXIT | |
| 14 | ABEO | Abeona Therapeutics Inc | Stock-Other | 2.55% | -0.73% | — | |
| 15 | ✓ | Zevra Therapeutics Inc | Stock-Other | 2.17% | — | — | |
| 16 | IDN | Intellicheck Inc | Stock-Other | 1.96% | -1.45% | EXIT | |
| 17 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.84% | -1.84% | EXIT | |
| 18 | ARQ | Arq Inc | Stock-Other | 1.80% | — | -11.88% | |
| 19 | ARDX | Ardelyx Inc | Stock-Other | 1.62% | +1.03% | NEW | |
| 20 | BYRN | Byrna Technologies Inc | Stock-Other | 1.60% | — | — | |
| 21 | ✓ | Polypid LTD | Stock-Other | 1.41% | -0.47% | +26.09% | |
| 22 | COYA | Coya Therapeutics Inc | Stock-Other | 1.37% | -0.29% | -11.78% | |
| 23 | STX | Seagate Technology Holdings plc | Stock-Tech | 1.33% | — | -99.84% | |
| 24 | TLPH | Talphera Inc | Stock-Other | 1.29% | -0.17% | +4.65% | |
| 25 | APYX | Apyx Medical CORP | Stock-Other | 0.94% | -0.24% | — | |
| 26 | RNXT | Renovorx Inc | Stock-Other | 0.89% | -0.23% | +8.36% | |
| 27 | GRCE | Grace Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 28 | ELUT | Elutia Inc | Stock-Other | 0.51% | -0.34% | -3.06% | |
| 29 | NRXS | Neuraxis Inc | Stock-Other | 0.44% | -0.16% | — | |
| 30 | IPWR | Ideal Power Inc | Stock-Other | 0.37% | -0.16% | -4.10% | |
| 31 | SMTK | Smartkem Inc | Stock-Other | 0.17% | -0.03% | EXIT | |
| 32 | QNRX | Quoin Pharmaceuticals Lt-adr | Stock-Other | 0.17% | -0.03% | — | |
| 33 | BFRI | Biofrontera Inc | Stock-Other | 0.13% | -0.06% | -12.51% | |
| 34 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.08% | -0.06% | -31.29% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SNDK | Sandisk CORP | +7.2% | — | Unchanged |
| 2 | DAWNGBX | Day One Biopharmaceuticals I | +1.5% | +31.01% | Add |
| 3 | BKTI | Bk Technologies CORP | +1.5% | +113.57% | Add |
| 4 | CSTL | Castle Biosciences Inc | +1.3% | -11.67% | Trim |
| 5 | ESPR | Esperion Therapeutics Inc | +1.3% | +33.33% | Add |
| 6 | ARDX | Ardelyx Inc | +1.3% | +479.35% | Add |
| 7 | FENC | Fennec Pharmaceuticals Inc | +1.2% | +132.06% | Add |
| 8 | LRMR | Larimar Therapeutics Inc | +0.9% | +100.00% | Add |
| 9 | LPTH | Lightpath Technologies Inc-a | +0.7% | +14.53% | Add |
| 10 | LASR | Nlight Inc | +0.4% | — | Unchanged |
| 11 | ✓ | Polypid LTD | +0.4% | +26.09% | Add |
| 12 | TLPH | Talphera Inc | +0.2% | +4.65% | Add |
| 13 | NRXS | Neuraxis Inc | +0.1% | — | Unchanged |
| 14 | GRCE | Grace Therapeutics Inc | — | — | Unchanged |
| 15 | SMTK | Smartkem Inc | 0% | +58.72% | Add |
| 16 | RNXT | Renovorx Inc | -0.1% | +8.36% | Add |
| 17 | APRE | Aprea Therapeutics Inc | -0.1% | -31.29% | Trim |
| 18 | BFRI | Biofrontera Inc | -0.2% | -12.51% | Trim |
| 19 | ELUT | Elutia Inc | -0.3% | -3.06% | Trim |
| 20 | IPWR | Ideal Power Inc | -0.4% | -4.10% | Trim |
| 21 | COYA | Coya Therapeutics Inc | -0.4% | -11.78% | Trim |
| 22 | PSNL | Personalis Inc | -1.6% | -25.49% | Trim |
| 23 | DOMO | Domo Inc - Class B | -2.2% | +36.99% | Add |
| 24 | ARQ | Arq Inc | -3.4% | -11.88% | Trim |
| 25 | STX | Seagate Technology Holdings plc | -9.4% | -99.84% | Trim |
| 26 | ZM | Zoom Communications, Inc. | — | NEW | New buy |
| 27 | ZVRA | Zevra Therapeutics Inc | — | EXIT | Sold out |
| 28 | MXL | Maxlinear Inc | — | EXIT | Sold out |
| 29 | VNDA | Vanda Pharmaceuticals Inc | — | NEW | New buy |
| 30 | LUMN | Lumen Technologies Inc | — | EXIT | Sold out |
| 31 | KYTX | Kyverna Therapeutics Inc | — | NEW | New buy |
| 32 | GLW | Corning Inc | — | EXIT | Sold out |
| 33 | MBLY | Mobileye Global Inc-a | — | EXIT | Sold out |
| 34 | ABEO | Abeona Therapeutics Inc | — | NEW | New buy |
| 35 | APPS | Digital Turbine Inc | — | EXIT | Sold out |
| 36 | ✓ | Zevra Therapeutics Inc | — | NEW | New buy |
| 37 | IDN | Intellicheck Inc | — | NEW | New buy |
| 38 | VPG | Vishay Precision Group | — | EXIT | Sold out |
| 39 | BYRN | Byrna Technologies Inc | — | NEW | New buy |
| 40 | VELO | Velo3d Inc | — | EXIT | Sold out |
| 41 | PHAT | Phathom Pharmaceuticals Inc | — | EXIT | Sold out |
| 42 | AMBA | Ambarella, Inc. | — | EXIT | Sold out |
| 43 | APYX | Apyx Medical CORP | — | NEW | New buy |
| 44 | VUZI | Vuzix CORP | — | EXIT | Sold out |
| 45 | ELVA | Electrovaya Inc | — | EXIT | Sold out |
| 46 | QNRX | Quoin Pharmaceuticals Lt-adr | — | NEW | New buy |
According to official SEC Form 13F filings, AIGH Capital Management LLC reported a total U.S. public equity portfolio value of $1.6B across 34 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SNDK, ZM, CSTL) accounted for 12.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
ZM
市值: $60.4M
Top Position Liquidated / Trimmed
ZVRA
前期市值: $19.4M
During Q4 2025, AIGH Capital Management LLC's top holdings by market value included SNDK (16.1%)、ZM (14.6%)、CSTL (5.9%). The largest single position, SNDK, represented 16.1% of total portfolio value.
In Q4 2025, AIGH Capital Management LLC made 42 total portfolio adjustments, initiating 9 new buys, adding to 12 positions, trimming 9 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.